The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients
Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety ris
Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety ris This story matters for Health & Wellness readers tracking wellness. Reported by sciencedaily.com. Read the full original at the source link below.
Originally reported by sciencedaily.com. WellnessNews curates and briefs the health & wellness stories that matter. Our editorial policy →